- Raw materials
- Anticancer drugs
- Tipapkinogene sovacivec
Tipapkinogene sovacivec API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Tipapkinogene sovacivec | CAS No: 1052105-48-2 | GMP-certified suppliers
A medication that targets cervical and vulvar dysplasia, carcinoma, and HPV-related viral infections by inducing immune responses against infected and transformed cells.
Primary indications
- Investigated for use/treatment in cervical dysplasia/cancer, viral infection, and vulvar dysplasia and carcinoma
Product Snapshot
- Tipapkinogene sovacivec is a gene therapy formulation
- It is investigated primarily for cervical dysplasia, cervical cancer, viral infections, and vulvar dysplasia and carcinoma
- The product is currently in an investigational status with no approved regulatory market authorization
Clinical Overview
The mechanism of action of tipapkinogene sovacivec involves the delivery and expression of HPV16 oncogenic proteins E6 and E7 by the MVA vector. These viral oncoproteins are presented to the immune system via major histocompatibility complex (MHC) class I and II pathways, inducing antigen-specific cellular and humoral immune responses. This targeted immunogenicity facilitates recognition and elimination of HPV-infected or transformed cells. In addition to antigen-specific stimulation, the presence of the vaccinia virus and the included interleukin-2 (IL-2) gene serves as an immunologic adjuvant, potentially enhancing innate and adaptive immune activation non-specifically.
Pharmacokinetic and absorption, distribution, metabolism, and excretion (ADME) data are not publicly detailed due to the investigational nature of this immunotherapy. Clinical safety evaluations emphasize the attenuated viral vector’s established safety profile, derived from extensive prior use of MVA-based platforms. However, the use of live recombinant viral vectors necessitates monitoring for potential immune-related adverse events and contraindications in immunocompromised populations.
Tipapkinogene sovacivec is not yet commercially approved and remains under clinical investigation. It may hold therapeutic potential both as monotherapy in lower-grade cervical intraepithelial neoplasia and in combination with existing treatments for more advanced cervical malignancies.
For API sourcing, stringent quality control is essential given the biologically complex nature of recombinant viral vectors. Manufacturing should comply with current Good Manufacturing Practices (cGMP) standards, ensuring viral vector identity, purity, potency, and absence of replication-competent vaccinia virus. Reliable supply chains must maintain cold chain logistics and rigorous sterility assurance to preserve product integrity for clinical use.
Identification & chemistry
| Generic name | Tipapkinogene sovacivec |
|---|---|
| Molecule type | Biotech |
| CAS | 1052105-48-2 |
| UNII | P34L5Y2SR5 |
| DrugBank ID | DB06239 |
Pharmacology
| Summary | TG 4001 is a therapeutic vaccine utilizing a modified vaccinia virus Ankara (MVA) vector to deliver HPV16 E6 and E7 antigens, eliciting antigen-specific cellular and humoral immune responses through MHC class I and II presentation. The vaccine also promotes non-specific immune activation via the vaccinia virus vector and an IL-2 adjuvant. It is investigated for targeting HPV-associated cervical and vulvar dysplasia and neoplasia. |
|---|---|
| Mechanism of action | TG 4001 is based on the modified vaccinia virus Ankara (MVA virus) carrying and expressing HPV16 E6 and E7 genes. The MVA vector is a highly attenuated strain of vaccinia virus that combines an extensive history of safety with the ability to stimulate a strong immune response to antigens. The TG 4001 therapeutic vaccine induces specific immunity by presentation of E6 and E7 antigens to T cells via major histocompatibility complex (MHC) class I and II inducing specific cellular and humoral responses. A second mechanism may be a non-specific activation of the immune system via the vaccinia virus and the interleukin 2 (IL2) adjuvant of the immune response. TG 4001 could have further applications beyond Cervical Intraepithelial Neoplasia (CIN) 2/3 as a single agent in low grade CIN (CIN1) or cervical cancers in combination with existing treatments. [Transgene press release] |
Formulation & handling
- Tipapkinogene sovacivec is a biotech investigational agent typically formulated for parenteral administration. The solid state indicates a need for reconstitution before use, requiring aseptic handling. As a protein-based product, it may require cold chain storage to maintain stability.
Regulatory status
Tipapkinogene sovacivec is a type of Anticancer drugs
Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.
Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.
These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.
Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.
